Handelsavisen
prelaunch
Companies Healthcare ORTIB.ST
OR
ORTIB.ST Nasdaq Stockholm Advanced Medical Equipment & Technology

Ortivus AB

Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-27,0 %
ROE
-97,6 %
Net margin
-29,8 %
Debt / equity
0,87
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Ortivus AB is a provider of advanced medical equipment and technology, primarily generating revenue through the development, production, and sale of medical devices and related services.

Business. Ortivus AB (ORTIB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-97,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ORTIB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ORTIB.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ortivus AB (ORTIB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Ortivus AB has a liquidity position that is marginally balanced, with a current ratio of 0.98, indicating that its current liabilities slightly exceed its current assets. The company's liquidity is further constrained by a negative net cash position after subtracting total debt, which is a key flag in its risk assessment. The company's cash and equivalents amount to 8,888,000 SEK, while its long-term debt stands at 19,527,000 SEK, resulting in a debt-to-equity ratio of 0.87.

    Profitability metrics for Ortivus are weak, with a return on equity (ROE) of -0.976 and a return on assets (ROA) of -0.3084, both significantly below the industry median for Advanced Medical Equipment & Technology firms. The company reported a net loss of 21,876,000 SEK and an operating loss of 19,805,000 SEK, reflecting poor operational performance. Gross profit of 29,600,000 SEK is insufficient to cover operating expenses, contributing to the negative net income.

    Geographically and segment-wise, Ortivus does not disclose detailed revenue concentration data in the provided financials. However, the company operates in a specialized segment of the healthcare industry, and its business model is likely concentrated in a few core product lines or geographic regions, as is typical for firms in the Advanced Medical Equipment & Technology industry.

    The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. Historical revenue of 73,401,000 SEK suggests a relatively small revenue base, and the negative operating and free cash flows indicate that the company is not generating sufficient cash to sustain operations without external financing. The capital expenditure of -9,593,000 SEK suggests ongoing investment in infrastructure or equipment, but this is being funded by negative cash flows rather than positive operating performance.

    Risk factors for Ortivus include its liquidity constraints and the potential for dilution, although the risk of dilution is currently assessed as low. The company's negative net cash position and operating cash flow of -25,238,000 SEK raise concerns about its ability to meet short-term obligations without additional financing. The risk assessment also highlights the need for close monitoring of the company's capital structure and cash flow generation.

    Recent events, including the latest financial filing (market data), indicate that the company is in a challenging financial position. The operating and net losses, combined with negative cash flows, suggest that the company may need to secure additional financing or restructure its operations to improve its financial health.

    Key takeaways
    • Ortivus AB is a small-cap healthcare equipment firm with a weak profitability profile and negative cash flows.
    • The company's liquidity is constrained, with a current ratio of 0.98 and a negative net cash position after debt.
    • Return on equity and return on assets are significantly below industry medians, indicating poor capital efficiency.
    • The company is not generating sufficient cash to fund operations or capital expenditures.
    • The risk of dilution is currently low, but liquidity risk remains a concern.
    • No clear growth trajectory is evident from the provided data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    kr22.4M
    Net cash
    -kr10.6M
    Current ratio
    1.0
    Debt / equity
    0.9
    ROA
    -30.8%
    ROE
    -97.6%
    Cash conversion
    115.0%
    CapEx / revenue
    -13.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-27,0 %Below median
    Net Margin-29,8 %Below median
    ROE-97,6 %Bottom quartile
    Capex / Rev-13,1 %Bottom quartile
    D/E0,87Bottom quartile
    Cash Conv1,15Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Ortivus AB Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ORTIB.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage